VAV1 Degrader Enters Second Phase II Disease

Company Monte Rosa Therapeutics; Novartis Event Type Phase II initiation and milestone Modality Molecular-glue degrader Asset MRT-6160 (DDY391) Target VAV1 Disease Area Psoriatic arthritis; Sjögren disease Summary Monte Rosa said on 28 October that Novartis initiated a second Phase II study of licensed VAV1 molecular-glue…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Tags
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *

Saturday Rounds

Curium Agrees to Acquire Lantheus for Up to $8 Billion
Typewriter Launches with $56 Million for All-RNA Gene Insertion
Ligand Funds AvenCell CAR T Pipeline
US Cooperative Group Will Test Ivonescimab in Biliary Cancer